The European Commission has requested that the Virtual Physiological Human Institute (VPHi), the Academic Research Membership of the Avicenna Alliance, put forward suggestions for what they consider should be funding priorities in Horizon 2020.
The Avicenna Alliance has been in touch with the FDA on the issue of in silico medicine over the last number of months and has reached a new level of cooperation with the FDA looking into Observer Status in the Avicenna Alliance.
On 02 May 2016, Avicenna Alliance delegates me with representatives of DG Connect to discuss progress on in silico medicine in the 1st quarter of this year. The European Commission had good reason to be pleased at progress.
The European Commission has appointed the Virtual Physiological Human Institute (VPHi) to its eHealth Stakeholder Group. With VPHi representing 50% of the membership of Avicenna, this provides the Alliance access to a key influential group in Brussels.